Marinus R. Van Marwijk Kooy

Zwolle, OV, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Journal: Leukemia

Published: June 30, 2023

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 31, 2022

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.

Journal: Blood

Published: October 18, 2021

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial.

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial.

Journal: Blood advances

Published: July 30, 2021

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.

Journal: Blood advances

Published: November 18, 2020

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Journal: Leukemia

Published: August 01, 2020

Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).

Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 31, 2020

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.

Journal: The Lancet. Haematology

Published: January 29, 2020

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Journal: Leukemia

Published: October 16, 2019

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial.

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial.

Journal: Haematologica

Published: September 02, 2018

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Journal: The New England journal of medicine

Published: March 31, 2018

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Journal: Leukemia

Published: April 18, 2017

Showing 1-12 of 19

Last Updated: 09/26/2026